20 research outputs found
Interleukin-21 induces the differentiation of human umbilical cord blood CD34-lineage- cells into pseudomature lytic NK cells
<p>Abstract</p> <p>Background</p> <p>Umbilical cord blood (UCB) is enriched with transplantable CD34<sup>+ </sup>cells. In addition to CD34-expressing haematopoietic stem cells (HSC), human UCB contains a rare population of CD34<sup>-</sup>lineage<sup>- </sup>cells endowed with the ability to differentiate along the T/NK pathway in response to interleukin (IL)-15 and a stromal cell support. IL-21 is a crucial regulator of NK cell function, whose influence on IL-15-induced differentiation of CD34<sup>-</sup>lineage<sup>- </sup>cells has not been investigated previously. The present study was designed and conducted to address whether IL-21 might replace the stromal cell requirements and foster the IL-15-induced NK differentiation of human UCB CD34<sup>-</sup>lineage<sup>- </sup>cells.</p> <p>Results</p> <p>CD34<sup>-</sup>lineage<sup>- </sup>cells were maintained in liquid culture with Flt3-L and SCF, with the addition of IL-15 and IL-21, either alone or in combination. Cultures were established in the absence of feeder cells or serum supplementation. Cytokine-treated cells were used to evaluate cell surface phenotype, expression of molecular determinants of lymphoid/NK cell differentiation, secretion of IFN-γ, GM-CSF, TNF-α and CCL3/MIP-1α, and cytolytic activity against NK-sensitive tumour cell targets. CD34<sup>-</sup>lineage<sup>- </sup>cells proliferated vigorously in response to IL-15 and IL-21 but not to IL-21 alone, and up-regulated phosphorylated Stat1 and Stat3 proteins. CD34<sup>-</sup>lineage<sup>- </sup>cells expanded by IL-21 in combination with IL-15 acquired lymphoid morphology and killer-cell immunoglobulin-like receptor (KIR)<sup>-</sup>CD56<sup>+</sup>CD16<sup>-/+ </sup>phenotype, consistent with pseudo-mature NK cells. IL-21/IL-15-differentiated cells expressed high levels of mRNA for Bcl-2, GATA-3 and Id2, a master switch required for NK-cell development, and harboured un-rearranged TCRγ genes. From a functional standpoint, IL-21/IL-15-treated cells secreted copious amounts of IFN-γ, GM-CSF and CCL3/MIP-1α, and expressed cell surface CD107a upon contact with NK-sensitive tumour targets, a measure of exocytosis of NK secretory granules.</p> <p>Conclusion</p> <p>This study underpins a novel role for IL-21 in the differentiation of pseudo-mature lytic NK cells in a synergistic context with IL-15, and identifies a potential strategy to expand functional NK cells for immunotherapy.</p
Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies
<p>Abstract</p> <p>Background</p> <p>Pegylated granulocyte colony-stimulating factor (G-CSF; pegfilgrastim) is a longer-acting form of G-CSF, whose effects on dendritic cell (DC) and regulatory T cell (Treg) mobilization, and on the <it>in vivo </it>and ex vivo release of immune modulating cytokines remain unexplored.</p> <p>Methods</p> <p>Twelve patients with gynecological cancers received carboplatin/paclitaxel chemotherapy and single-dose pegfilgrastim as prophylaxis of febrile neutropenia. Peripheral blood was collected prior to pegfilgrastim administration (day 0) and on days +7, +11 and +21, to quantify immunoregulatory cytokines and to assess type 1 DC (DC1), type 2 DC (DC2) and Treg cell mobilization. <it>In vitro</it>-differentiated, monocyte-derived DC were used to investigate endocytic activity, expression of DC maturation antigens and ability to activate allogeneic T-cell proliferation.</p> <p>Results</p> <p>Pegfilgrastim increased the frequency of circulating DC1 and DC2 precursors. In contrast, CD4<sup>+</sup>FoxP3<sup>+ </sup><it>bona fide </it>Treg cells were unchanged compared with baseline. Serum levels of hepatocyte growth factor and interleukin (IL)-12p40, but not transforming growth factor-β1 or immune suppressive kynurenines, significantly increased after pegfilgrastim administration. Interestingly, pegfilgrastim fostered <it>in vitro</it> monocytic<it/> secretion of IL-12p40 and IL-12p70 when compared with unconjugated G-CSF. Finally, DC populations differentiated <it>in vitro </it>after clinical provision of pegfilgrastim were phenotypically mature, possessed low endocytic activity, and incited a robust T-cell proliferative response.</p> <p>Conclusions</p> <p>Pegfilgrastim induced significant changes in immune cell number and function. The enhancement of monocytic IL-12 secretion portends favorable implications for pegfilgrastim administration to patients with cancer, a clinical context where the induction of immune deviation would be highly undesirable.</p
Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures
<p>Abstract</p> <p>Background</p> <p>Cytokine-induced killer (CIK) cells are typically differentiated <it>in vitro </it>with interferon (IFN)-γ and αCD3 monoclonal antibodies (mAb), followed by the repeated provision of interleukin (IL)-2. It is presently unknown whether thymoglobulin (TG), a preparation of polyclonal rabbit γ immunoglobulins directed against human thymocytes, can improve the generation efficiency of CIK cells compared with αCD3 mAb in a clinical-grade culture protocol.</p> <p>Methods</p> <p>Peripheral blood mononuclear cells (PBMC) from 10 healthy donors and 4 patients with solid cancer were primed with IFN-γ on day 0 and low (50 ng/ml), intermediate (250 ng/ml) and high (500 ng/ml) concentrations of either αCD3 mAb or TG on day 1, and were fed with IL-2 every 3 days for 21 days. Aliquots of cells were harvested weekly to monitor the expression of representative members of the killer-like immunoglobulin receptor (KIR), NK inhibitory receptor, NK activating receptor and NK triggering receptor families. We also quantified the frequency of <it>bona fide </it>regulatory T cells (Treg), a T-cell subset implicated in the down-regulation of anti-tumor immunity, and tested the <it>in vitro </it>cytotoxic activity of CIK cells against NK-sensitive, chronic myeloid leukaemia K562 cells.</p> <p>Results</p> <p>CIK cells expanded more vigorously in cultures supplemented with intermediate and high concentrations of TG compared with 50 ng/ml αCD3 mAb. TG-driven CIK cells expressed a constellation of NK activating/inhibitory receptors, such as CD158a and CD158b, NKp46, NKG2D and NKG2A/CD94, released high quantities of IL-12p40 and efficiently lysed K562 target cells. Of interest, the frequency of Treg cells was lower at any time-point compared with PBMC cultures nurtured with αCD3 mAb. Cancer patient-derived CIK cells were also expanded after priming with TG, but they expressed lower levels of the NKp46 triggering receptor and NKG2D activating receptor, thus manifesting a reduced ability to lyse K562 cells.</p> <p>Conclusions</p> <p>TG fosters the generation of functional CIK cells with no concomitant expansion of tumor-suppressive Treg cells. The culture conditions described herein should be applicable to cancer-bearing individuals, although the differentiation of fully functional CIK cells may be hindered in patients with advanced malignancies.</p
M tuberculosis in the adjuvant modulates time of appearance of CNS-specific effector T cells in the spleen through a polymorphic site of TLR2
DC deliver information regulating trafficking of effector T cells along T-cell priming. However, the role of pathogen-derived motives in the regulation of movement of T cells has not been studied. We hereinafter report that amount of M tuberculosis in the adjuvant modulates relocation of PLP139-151 specific T cells. In the presence of a low dose of M tuberculosis in the adjuvant, T cells (detected by CDR3 BV-BJ spectratyping, the so-called "immunoscope") mostly reach the spleen by day 28 after immunization ("late relocation") in the SJL strain, whereas T cells reach the spleen by d 14 with a high dose of M tuberculosis ("early relocation"). The C57Bl/6 background confers a dominant "early relocation" phenotype to F1 (SJL
7C57Bl/6) mice, allowing early relocation of T cells in the presence of low dose M tuberculosis. A single non-synonymous polymorphism of TLR2 is responsible for "early/late" relocation phenotype. Egress of T lymphocytes is regulated by TLR2 expressed on T cells. Thus, pathogens engaging TLR2 on T cells regulate directly T-cell trafficking, and polymorphisms of TLR2 condition T-cell trafficking upon a limiting concentration of ligand
A new standardized clinical-grade protocol for banking human umbilical cord tissue cells
BACKGROUND: Mesenchymal stromal cells (MSCs) isolated from human umbilical cord
tissue (UCT) can be considered the perfect candidates for cell-based therapies
and regenerative medicine. UCT-derived MSCs can be cryogenically stored in cell
banks and expanded as needed for therapeutic uses.
STUDY DESIGN AND METHODS: We developed a new method for UCT-MSC isolation,
cryopreservation, and expansion, following all criteria required by a stem cell
bank. UCT-MSCs were isolated either by manual dissociation (MM) or by a
semiautomatic dissociation system (SAM). In both protocols UCTs were treated
enzymatically using Type IV collagenase good manufacturing practices (GMP) graded
and hyaluronidase (medicinal product). Isolated UCT-MSCs were cryopreserved and
analyzed after thawing for phenotype; for proliferation rate; and for their
osteogenic, adipogenic, and chondrogenic differentiation capabilities.
RESULTS: We found that SAM reduced the time of tissue enzyme exposure and enabled
us to obtain a homogeneous single-cell suspension deprived of tissue fragments.
The isolated cells in both groups showed high expression of MSC markers CD105,
CD73, and CD90 and similar differentiation capabilities, phenotype, and
proliferation potential. Moreover, the final yield of MSCs was comparable between
the two techniques.
CONCLUSION: In this study, we have established a reliable and standardized
protocol to isolate UCT-MSCs from UCT for cell banking purposes. Processing the
whole umbilical tissue with GMP-graded enzymes using a semiautomatic dissociator
allowed us to obtain a single-cell suspension product with a known number of
isolated cells that can be cryopreserved right after isolation and thawed as
needed for expansion and clinical use
S1703 Tregs (FOXP3+CD4+) in Peripheral Blood of Patients with Inflammatory Bowel Disease (IBD) During Treatment with Anti TNFα Agents
1042-85 Tumor necrosis factor-α blockade: A key inhibition to modulate the inflammatory response in patients with unstable angina?
CD34-positive cells in human umbilical cord blood express nerve growth factor and its specific receptor TrkA
In this study, we investigated whether hematopoietic stem cells (HSC) and progenitors present in human cord blood can express nerve growth factor (NGF)-specific receptors, TrkA and p75. Our results showed a marked expression of TrkA and NGF in cord blood CD34+ cells. A gradient of TrkA and NGF expression exists and is highest in cord blood CD34+ cells, reduced in cord blood mononuclear cells (MNC) and minimal in mononuclear cells isolated from adult peripheral blood. Our findings suggest that NGF may play a role in the differentiation of hematopoietic progenitors and indicate a different requirement for NGF by immune cells, depending on their state of maturity. © 2003 Elsevier Science B.V. All rights reserved